AURKA is a possible prognostic biomarker for the progression of high-risk small-cell PCa because it has been established to strengthen in 67% of PCa patients with highly aggressive hormone-naive castration-resistant cancer [74]. Here, AURKA is linked to posterior cortical atrophy.